Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678162 | 0.79 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL467371 | 0.78 | SIGMAR1 (0.97) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL12648455 | 0.78 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL10975840 | 0.73 | CYP3A4 (0.82) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL5681292 | 0.71 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL2830423 | 0.71 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL7429031 | 0.71 | SIGMAR1 (0.74) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL3385087 | 0.71 | SIGMAR1 (0.64) | SIGMAR1CYP3A4MAPT | |
| SCHEMBL5935280 | 0.70 | SIGMAR1 (0.80) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL1780137 | 0.70 | SIGMAR1 (0.97) | SIGMAR1TP53CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170176446-A1 | Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-06-22 | — | — | US | disclosed |
| US-20140221353-A1 | Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer | AFFICHEM (FR) | 2014-08-07 | — | — | US | disclosed |
| US-20120100124-A1 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170176446-A1 | Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer | MYC, CCNO, MKI67 | SIGMAR1 2131/4885TP53 6/4885CYP1A2 3196/4885 |
| US-20120100124-A1 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER | MYC, CCNO, MKI67 | SIGMAR1 2131/4885TP53 6/4885CYP1A2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.